

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 September 2006 (21.09.2006)

PCT

(10) International Publication Number
WO 2006/097323 A1

(51) International Patent Classification:
C07D 217/24 (2006.01) A61P 35/00 (2006.01)
A61K 31/435 (2006.01)

(21) International Application Number:
PCT/EP2006/002471

(22) International Filing Date: 17 March 2006 (17.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10 2005 012 680.4 18 March 2005 (18.03.2005) DE

(71) Applicant and

(72) Inventor (for all designated States except US): **WEBER, Lutz** [DE/DE]; Edelweiss Strasse 8, 82110 Germering (DE).

(74) Agents: **FORSTMAYER, Dietmar** et al.; **BOETERS & LIECK**, Bereiteranger 15, 81541 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER



(I)

(57) Abstract: The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events, heart valvular degenerative disease. Moreover, compounds of formula (I) can be used to decrease the side effects from cytotoxic cancer agents and to treat viral infections.

TETRAHYDRO-ISOQUINOLIN-1-ONES FOR THE TREATMENT OF CANCER

BACKGROUND OF THE INVENTION

5

HDM2 plays a central role in regulating and influencing important cell-signalling pathways. HDM2 is known to interact with a range of different proteins that influence cellular apoptosis, proliferation and survival.

10

Thus, amongst other proteins, HDM2 binds to the tumor suppressor protein p53 and targets this protein for ubiquitination and degradation, prevents translocation of p53 to the nucleus by facilitating translocation to the microsomes. Thereby, HDM2 prevents transactivation of p53 target genes that are implicated in the regulation of cell cycle and apoptosis. The p53 protein is a potent cell cycle inhibitor that prevents propagation of permanently damaged cell clones by the induction of growth arrest or apoptosis, resulting in the protection against development of cancer by guarding cellular integrity.

20

Both p53 as well as HDM2 can be associated with cancer: about 50% of all human tumors harbor a mutation or deletion in the p53 gene that impairs normal p53 function (Hollstein et al. *Science* **1991**, 253, 49-53). In many cancers with wild-type p53, HDM2 is overexpressed, disabling the normal p53 function (Momand et al. *Nucleic Acids Res.* **1998**, 26, 3453-3459).

25

The HDM2 gene has a p53-responsive promoter element and elevated levels of p53 that translocate to the nucleus induce expression of HDM2. Induction of HDM2 by p53 forms an autoregulatory

30

- 2 -

feedback loop, ensuring low levels of both HDM2 and p53 in normally proliferating cells (Michael and Oren *Semin. Cancer Biol.* 2003, 13, 49-58; Vousden and Lu *Nature Reviews Cancer* 2002, 2, 594-604). However, in many cancers this normal ratio of HDM2 to p53 is changed and misregulated.

Inhibiting the interaction of HDM2 with p53 in cells with wild-type p53 or mutated p53 should lead to an increase of p53 levels in the cytosole, facilitating normal nuclear translocation of normal or mutated p53, cell cycle arrest and/or apoptosis and restoring the tumor suppressor role of p53. The feasibility of this strategy has been shown by the use of different macromolecular tools for inhibition of HDM2-p53 interaction (e.g. antibodies, antisense oligonucleotides, peptides).

HDM2 also binds to the tumor suppressor pRB, as well as E2F-1 (Yang et al. *Clinical Cancer Research* 1999, 5, 2242-2250).

E2F-1 is a transcription factor that regulates S phase entry and has been shown to cause apoptosis in some cell types when overexpressed. HDM2 binds to E2F through a conserved binding region at p53, activating E2F-dependent transcription of cyclin A, and suggesting that HDM2 small molecule ligands or antagonists might have also anti-tumor effects in cells independent of their role of restoring p53 function.

HDM2 can associate *in vitro* and *in vivo* with the mammalian Numb protein. The association occurs through the N-terminal domain of HDM2, which is the region also involved in p53 binding. The Numb protein is involved in the regulation of cell fate and in a variety of developmental processes, most notably in the nervous

- 3 -

system. Through its interaction with Numb, HDM2 may influence processes such as differentiation and survival. This could also contribute to the altered properties of tumor cells, which overexpress HDM2 (Juven-Gershon et al. *Mol. Cell. Biol.* **1998**, *18*, 3974-3982).

There is also evidence that HDM2 has a direct role in the regulation of p21, a cyclin-dependent kinase inhibitor. The inhibition of HDM2 with anti-HDM2 antisense oligonucleotide or Short Interference RNA targeting HDM2 significantly elevates p21 protein levels in p53 null PC3 cells. In contrast, overexpression of HDM2 diminishes p21 levels by shortening the p21 half-life, an effect reversed by HDM2 antisense inhibition. HDM2 facilitates p21 degradation independent of ubiquitination and the E3 ligase function of HDM2. Instead, HDM2 promotes p21 degradation by facilitating binding of p21 with the proteasomal C8 subunit. The p21 and HDM2 bind through 180-the 298 amino acids region of the HDM2 protein (Zhang et al. *J. Biol. Chem.* **2004**, *279*, 16000-16006).

There is also evidence for a malfunctioning HDM2 regulation having effect on a proper p53 function and causing cancer, beyond mutated p53 or overexpression of HDM2. Thus, when E2F signals the growth of a cancer, P14ARF is dispatched to break down HDM2, freeing p53 to kill the cancer cell. In certain cancers P14ARF is lacking (Moule et al. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 14063-6). P14ARF binds to HDM2 and promotes the rapid degradation of HDM2. ARF-mediated HDM2 degradation is associated with HDM2 modification and concurrent p53 stabilization and accumulation.

30

- 4 -

The validity of inhibiting HDM2 as a therapeutic concept has been first demonstrated by antisense HDM2 inhibitors that exhibit significant antitumor activity in multiple human cancer models with various p53 statuses (Zhang et al. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 11636-11641).

Small molecule antagonists of the HDM2 protein interactions may therefore offer a viable approach towards cancer therapy, either as single agents or in combination with a broad variety of other anti-tumor therapies.

There is also growing evidence that HDM2 plays an important role in viral infections. First, it is known that viruses rely on changing normal p53 signalling (O'shea and Fried M. *Cell Cycle* **2005**; Machida et al. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *23*, 101, 4262-7).

Second, HDM2 directly interacts with viral proteins, for example HDM2 is a target of simian virus 40 in cellular transformation and during lytic infection (Henning et al. *J. Virol.* **1997**, *71*, 7609-7618). Furthermore, the HDM2 protein, like p53, becomes metabolically stabilized in SV40-transformed cells. This suggests the possibility that the specific targeting of HDM2 by SV40 is aimed at preventing HDM2-directed proteasomal degradation of p53 in SV40-infected and -transformed cells, thereby leading to metabolic stabilization of p53 in these cells. A trimeric LT-p53-HDM2 complex is formed with simian virus 40 large tumor antigen (LT) in SV40-transformed cells.

The human immunodeficiency virus type 1 (HIV-1) encodes a potent transactivator, Tat. HDM2 has been shown to interact with Tat and

mediating its ubiquitination *in vitro* and *in vivo*. In addition, HDM2 is a positive regulator of Tat-mediated transactivation, indicating that the transcriptional properties of Tat are stimulated by ubiquitination (Bres et al. *Nat Cell Biol.* **2003**, 5, 754-61).

Small molecule inhibitors of the HDM2 interaction have been reported and show pro-apoptotic effects in *in vitro* models and an antitumor effect in animal models of cancer. Thus, benzodiazepines have been used as a chemical scaffold to achieve HDM2 inhibitory activity (Grasberger et al. *J. Med. Chem.* **2005**, 48, 909-912; Parks et al. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15, 765-770). Similarly, imidazolines (Vassilev et al. *Science* **2004**, 303, 844-848), isoindolones (Hardcastle et al. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15, 1515-1520), norbornanes (Zhao et al. *Cancer Letters* **2002**, 183, 69-77) and sulfonamides (Galatin and Abraham *J. Med. Chem.* **2004**, 47, 4163-4165) have been reported as small molecule HDM2 inhibitors.

It has also been reported that HDM2 ligands have a cytoprotective effect. Thus, HDM2 inhibitors can be employed in methods of inducing cytoprotection and are useful to protect non-target cells against the harmful effects of chemotherapeutic agents. The amount of HDM2 inhibitor that provides such an effect can be about 5 to about 10 fold lower than the amount needed to induce apoptosis (Koblish et al. WO03095625, METHOD FOR CYTOPROTECTION THROUGH HDM2 AND HDM2 INHIBITION, 2003-11-20).

Isoquinolones have been reported already as potent antagonists of the platelet glycoprotein IIb-IIIa (Fisher et al. *J. Med. Chem.* **1997**, 40, 2085-2101) to treat cardiovascular diseases.

Pancrastatin is a naturally occurring alkaloid with an isoquinolone structure exhibiting anticancer properties, by acting on the tubulin cytoskeleton. Lysolipin and Cervinomycin are antibiotics isolated from *streptomyces violaceoniger*.

5 Lycoricidine and narciclasine are isoquinolone based plant-growth regulators, Gliquidone is an antidiabetic medication which is used in those patients with adult maturity onset or non-insulin dependent diabetes (NIDDM). It works by lowering blood sugar levels by stimulating the production and release of insulin from
10 the pancreas. It also promotes the movement of sugar from the blood into the cells in the body which need it. Tesicam is an isoquinolon-dione used for its anti-inflammatory properties. These compounds have low toxicity, good pharmaco-kinetic properties and render the chemical class of isoquinolones an
15 interesting scaffold for new drug candidates.

In this present invention, we describe novel, isoquinolone scaffold based small molecules that are inhibitors of HDM2 and can be used as novel therapeutic agents.

20 21 SUMMARY OF THE INVENTION

The present invention provides compounds of formula I and the
25 pharmaceutically acceptable salts and esters thereof, which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. This therapeutic effect can be achieved by using compounds of formula I alone or in combination with other agents
30 that are used to treat cancer.

- 7 -

Second, compounds of formula I also can be used to treat cancer by protecting non-cancer cells from the deleterious effects of cancer treating drugs. In this treatment, a combination of an antineoplastic agent and a cytoprotective amount of at least one
5 compound of formula I, and one or more pharmaceutically acceptable excipients are used. The compound of formula I, also called a HDM2 ligand is administered prior to, concurrently or after administration of the antineoplastic agent. Additionally, the HDM2 inhibitor can be administered continuously or at
10 repeated regular intervals.

Third, a compound of formula I can be used as a therapeutic agent in methods of treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease,
15 injury from ischemic events, heart valvular degenerative disease or decreasing the side effects from cytotoxic agents, such as hair loss or cardio toxicity induced by doxorubicin.

Fourth, a compound of formula I of the present invention can be
20 used to treat viral infections, especially in a pharmaceutical composition comprising a known antiviral compound.


Fifth, a compound of formula I of the present invention is directed to a pharmaceutical composition comprising a
25 cytoprotective amount of an HDM2 ligand, and one or more pharmaceutically acceptable excipients.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides isoquinolinone derivatives that are small molecule ligands of the HDM2 protein and prevent binding of other proteins to HDM2.

In *in vitro* cell-free and cell-based assays, compounds of the present invention inhibit the interaction of the HDM2 protein with a p53-derived peptide. In cell-based assays, these compounds demonstrate mechanistic activity such as induction of apoptosis and inhibition of proliferation. Incubation of cancer cells with wild-type p53 leads to accumulation of p53 protein, induction of p53-regulated p21 gene, and cell cycle arrest in G1 and G2 phase, resulting in potent antiproliferative activity against wild-type p53 cells *in vitro*. In contrast, these activities were not observed in cancer cells with mutant p53 at comparable compound concentrations. Therefore, the activity of HDM2 antagonists is likely linked to its mechanism of action. These compounds can be potent and selective anticancer agents.

The present invention provides a compound of formula I and pharmaceutically acceptable esters and salts thereof,



formula I

wherein R1 is selected from substituted or unsubstituted morpholinyl, substituted or unsubstituted pyrrolidinyl and substituted or unsubstituted piperazinyl, -O(X1) or -NX1(X2), with X1 and X2 independently selected from H, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein R2 and R3 are independently selected from aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein R4 is selected from -H, -F, -Cl, -Br, -I, -NO2, hydroxy, lower alkyl, lower alkenyl or lower alkynyl, lower alkoxy, such as -OCH3, -CH2OCH3 and -CH2OCH2CH3, -NY1(Y2), with Y1 and Y2 independently selected from H, lower alkyl, lower alkoxy alkyl, hetero alkyl, aryl or heteroaryl.

A preferred embodiment of the present invention relates to compounds of formula I, wherein R1 is selected from substituted or unsubstituted morpholinyl, substituted or unsubstituted pyrrolidinyl and substituted or unsubstituted piperazinyl, -O(X1) or -NX1(X2), with X1 and X2 independently selected from H, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, and R2 and R3 are each independently selected from aryl, heteroaryl, 1H-indol-3-yl, naphthal-2-yl, quinolin-3-yl, phenyl, substituted phenyl, 3- or 4-fluorophenyl, 3- or 4-chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl, benzyl, substituted benzyl, 3- or 4-fluorobenzyl, 3- or 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl and R4 is selected from -H, -F, -Cl, -Br, -I, -NO2, hydroxy, lower alkyl, lower alkenyl or lower alkynyl, lower alkoxy, such as -OCH3, -CH2OCH3 and -CH2OCH2CH3, -NY1(Y2), with Y1 and Y2 independently selected from H, lower alkyl, lower alkoxy alkyl, hetero alkyl, aryl or heteroaryl.

A further preferred embodiment of the present invention relates to compounds of formula I, wherein

5 R2 is selected from phenyl, substituted phenyl, 1H-indol-3-yl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorophenyl, 3- or 4-chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl and R3 is selected from benzyl, substituted benzyl, 1H-indol-3-methyl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorobenzyl, 3- or 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl.

10

A further preferred embodiment of the present invention relates to compounds of formula I, wherein

15 R2 is selected from benzyl, substituted benzyl, 1H-indol-3-methyl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorobenzyl, 3- or 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl and R3 is selected from phenyl, substituted phenyl, 1H-indol-3-yl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorophenyl, 3- or 4-chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl.

20 A further preferred embodiment of the present invention relates to compounds of formula I, wherein

R1 is selected from dimethylaminy1, diethylaminy1, morpholinyl, piperazinyl, N-methyl-piperazinyl, N-acetyl-piperazinyl, N-2-hydroxyethyl-piperazinyl, 2-oxo-N-alkyl-piperazinyl, 2-oxo-N-heteroalkyl-piperazinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl or 2-carboxy-pyrrolidinyl.

25

A further preferred embodiment of the present invention relates to compounds of formula I, wherein

30 R1 is selected from -OX1 or -NH(X2), wherein X1 is selected from -H or lower alkyl, and X2 is selected from H, -CH2CH2OH,

-CH₂CH₂OCH₃, lower alkyl, lower heteroalkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl.

A further preferred embodiment of the present invention relates
5 to compounds of formula I, wherein

R₁ is selected from -OX₁ or -NH(X₂), wherein X₁ is selected from
-H or lower alkyl, and X₂ is selected from H, -CH₂CH₂OH,
-CH₂CH₂OCH₃, lower alkyl, lower heteroalkyl, cycloalkyl,
heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl and
10 R₂ is selected from phenyl, substituted phenyl, 1H-indol-3-yl,
naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorophenyl, 3- or 4-
chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl and R₃ is
selected from benzyl, substituted benzyl, 1H-indol-3-methyl,
naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorobenzyl, 3- or 4-
15 chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl and
R₄ is selected from -H, -F, -Cl, -Br, -I, -NO₂, hydroxy, lower
alkyl, lower alkenyl or lower alkynyl, lower alkoxy, such as
-OCH₃, -CH₂OCH₃ and -CH₂OCH₂CH₃, -NY₁(Y₂), with Y₁ and Y₂
independently selected from H, lower alkyl, lower alkoxy alkyl,
20 hetero alkyl, aryl or heteroaryl.

A further preferred embodiment of the present invention relates
to compounds of formula I, wherein

R₁ is selected from -OX₁ or -NH(X₂), wherein X₁ is selected from
25 -H or lower alkyl, and X₂ is selected from H, -CH₂CH₂OH,
-CH₂CH₂OCH₃, lower alkyl, lower heteroalkyl, cycloalkyl,
heteroalkyl, aryl, heteroarylalkyl, aryl or heteroarylalkyl and
R₂ is selected from benzyl, substituted benzyl, 1H-indol-3-
methyl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorobenzyl, 3- or
30 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl and R₃ is
selected from phenyl, substituted phenyl, 1H-indol-3-yl,

naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorophenyl, 3- or 4-chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl and R4 is selected from -H, -F, -Cl, -Br, -I, -NO2, hydroxy, lower alkyl, lower alkenyl or lower alkynyl, lower alkoxy, such as -OCH3, -CH2OCH3 and -CH2OCH2CH3, -NY1(Y2), with Y1 and Y2 independently selected from H, lower alkyl, lower alkoxy alkyl, hetero alkyl, aryl or heteroaryl.

A further preferred embodiment of the present invention relates to compounds selected from the group of: 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2,3-Bis-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 3-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2-(4-Chloro-benzyl)-3-(1H-indol-3-yl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; (4-Chloro-phenyl)-[3-(4-chloro-phenyl)-4-(2-methoxy-ethylcarbamoyl)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid; 2-(4-Chloro-benzyl)-1-oxo-3-quinolin-3-yl-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2-(4-Chloro-benzyl)-3-naphthalen-2-yl-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2,3-Bis-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 3-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-(1H-indol-3-yl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-[Carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-(4-Chloro-

benzyl)-1-oxo-3-quinolin-3-yl-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4-(morpholine-4-carbonyl)-3,4-dihydro-2H-isoquinolin-1-one; 4-(4-Acetyl-piperazine-1-carbonyl)-2-(4-chloro-benzyl)-3-(4-chloro-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; 4-(4-Acetyl-piperazine-1-carbonyl)-2-(4-chloro-benzyl)-3-(4-chloro-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-hydroxy-ethyl)-amide; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,4-dihydro-2H-isoquinolin-1-one.

The present invention further provides pharmaceutical compositions comprising a compound of formula I as defined herein or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in combination with a pharmaceutically acceptable carrier.

A further preferred embodiment of the present invention relates to pharmaceutical compositions comprising a compound of formula I as defined herein or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in combination with a pharmaceutically acceptable carrier, further comprising one or more other anti-tumor agents.

A further preferred embodiment of the present invention relates to pharmaceutical compositions comprising a compound of formula I as defined herein or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in combination with a pharmaceutically acceptable carrier, further comprising one or more other anti-tumor agents,

- 14 -

wherein the anti-tumor agent is selected from 16-Aza-epothilone B, Aldesleukin, Amifostine, Aranose, Bevacizumab, Bleocin, Bleomycin, BMS-184476, Bortezomib, Calcitriol, Carmustine, Canertinib, Canfosfamide, Capecitabine, Carboplatin, Carmustine, 5 Cefixime, Ceftriaxone, Celecoxib, Celmoleukin, Cetuximab, Ciclosporin, Cisplatin, Clodronate, Cyclophosphamide, Cytarabine, Deoxorubicin, Desoxyepothilone B, Diethylstilbestrol, Diflomotecan, Docetaxel, Doxorubicin, Edatrexate, Efavoxir, EKB-569, Epirubicin, Epratuzumab, Erlotinib, Etoposide, Exatecan, 10 Fludarabine, Fluorouracil, Folinic acid, Galarubicin, Gefinitib, Gemcitabine, Gemtuzumab, Gimatecan, Glufosfamide, Granisetron, Homoharringtonine, Hyaluronic acid, Ibandronate, Ibritumomab, Ifosfamide, Imatinib, Interferon alfa, Interferon alfa-2a, Interferon alfa-2b, Irinotecan, Isoflavone, Isotretinoin, 15 Ixabepilone, Ketoconazole, Lapatinib, Leflunomide, Lenograstim, Leucovorin, Lexidronam, Linezolid, Lometrexol, Lurtotecan, MEN-10755, Methotrexate, Mitomycin, Neridronate, Nimesulide, Nitroglycerin, O6-Benzylguanine, Omeprazole, Ortataxel, Oxaliplatin, Paclitaxel, Patupilone, Pegfilgrastim, PEG- 20 filgrastim, Pelitinib, Pemetrexed, Pentostatin, Perifosine, Plevitrexed, Polyprenoic acid, Quinupristin, Raloxifene, Raltitrexed, Ramosetron, Retinoic acid, Risedronate, Rituximab, Rofecoxib, Rubitecan, S-9788, Sabarubicin, Sargramostim, Satraplatin, SN-38, Sorafenib, Suberanilohydroxamic acid, 25 Tamoxifen, Taxotere, Tazarotene, Tegafur, Temozolamide, Tesmilifene, Tetrodotoxin, Thalidomide, Tipifarnib, Topotecan, Trabectedin, Trastuzumab, Trastuzumab, Tretinoin, Vatalanib, Vincristine, Vinorelbine, Vinscris, ZD-6474, Zoledronate or Zosuquidar.

A further preferred embodiment of the present invention relates to pharmaceutical compositions comprising a compound of formula I as defined herein or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in
5 combination with a pharmaceutically acceptable carrier, further comprising one or more antitviral agents.

A further preferred embodiment of the present invention relates to pharmaceutical compositions comprising a compound of formula I
10 as defined herein or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in combination with a pharmaceutically acceptable carrier, further comprising one or more antitviral agents, wherein the antiviral agent is selected from 3TC, Abacavir,
15 Adefovir dipivoxil, Acyclovir, Amprenavir, Amantadine, Amoxovir, AZT, Clevudine, Delavirdine, d4T, Emtricitabine, Entecavir, Famciclovir, Ganciclovir, Indinavir, Lamivudine, Nelfinavir, Nevirapine, Oseltamavir, Rimantadine, Ritonavir, Saquinavir, Septrin, Telbivudine, Tenofovir, Valacyclovir, Valtorcitabine,
20 Valopicitabine or Zanamivir.

It is a further object of the present invention to provide for the use of a compound of formula I as defined herein or a pharmaceutical composition as defined herein for the preparation
25 of a medicament for the treatment of cancer.

The term alkyl denotes a saturated or unsaturated (i.e. alkenyl and alkynyl) straight or branched chain alkyl group, containing preferably from one to ten, more preferably one to six carbon
30 atoms for example methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, 2,2-

- 16 -

dimethylbutyl, n-octyl; ethenyl (vinyl), propenyl (allyl), iso-propenyl, n-pentyl, butenyl, isoprenyl or hexa-2-enyl; ethinyl, propinyl or butinyl groups. Any alkyl group as defined herein may be substituted with one, two or more substituents, for example F,
5 Cl, Br, I, NH₂, OH, SH, COOH or NO₂.

The terms alkenyl and alkynyl denote an unsaturated straight or branched chain alkyl group (having one, two or more double and/or triple bonds, an alkenyl preferably having one or two double
10 bonds and an alkynyl preferably having one or two triple bonds), containing preferably from two to ten, more preferably two to six carbon atoms for example: ethenyl (vinyl), propenyl (allyl), iso-propenyl, n-pentenyl, butenyl, isoprenyl or hexa-2-enyl; ethinyl, propinyl or butinyl groups. Any alkenyl or alkynyl group as
15 defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, NH₂, OH, SH, COOH or NO₂.

The term heteroalkyl denotes an alkyl group as defined herein where one or more carbon atoms are replaced by an oxygen,
20 nitrogen, phosphorous or sulphur atom for example an alkoxy group such as methoxy, ethoxy, propoxy, iso-propoxy, butoxy or tert.-butoxy, an alkoxyalkyl group such as methoxymethyl, ethoxymethyl, 1-methoxyethyl, 1-ethoxyethyl, 2-methoxyethyl or 2-ethoxyethyl, an alkylamino group such as methylamino, ethylamino, propylamino, isopropylamino, dimethylamino or diethylamino, an alkylthio group
25 such as methylthio, ethylthio or isopropylthio or a cyano group. It may also refer to one of the above groups containing a keto group. The term heteroalkyl furthermore refers to a group derived from a carboxylic acid or carboxylic acid amide such as acetyl,
30 propionyl, acetyloxy, propionyloxy, acetylamino or propionylamino, a carboxyalkyl group such as carboxymethyl,

carboxyethyl or carboxypropyl, a carboxyalkyl ester, an alkylthiocarboxyamino group, an alkoxyimino group, an alkylaminothiocarboxyamino group or an alkoxycarbonylamino group. Any heteroalkyl group as defined herein may be substituted with
5 one, two or more substituents, for example F, Cl, Br, I, NH₂, OH, SH, COOH or NO₂.

The term cycloalkyl refers to a saturated or partially unsaturated (having one, two or more double and/or triple bonds),
10 cyclic group with one, two or more rings, having preferably three to 14 carbon ring-atoms, more preferably from five or six to ten carbon ring-atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetralin, cyclopentenyl or cyclohex-2-enyl groups. Any cycloalkyl group as defined herein may be
15 substituted with one, two or more substituents, for example F, Cl, Br, I, OH, NH₂, SH, N₃, NO₂, alkyl groups such as methyl or ethyl, heteroalkyl groups as defined herein, such as methoxy, methylamino, dimethylamino, cyanide, or a group of the formula -OR₁₀, wherein R₁₀ is hydrogen, a group of formula PO(OR)₂ or
20 SO₃R or a heteroalkyl group carrying at least one OH, NH₂, SO₃R, PO(OR)₂ or COOH group, wherein R is H, alkyl, cycloalkyl, aryl, arylalkyl.

The term aryl refers to an aromatic cyclic group with one, two or
25 more rings, having preferably five to 14 carbon ring-atoms, more preferably from five or six to ten carbon ring-atoms, for example phenyl or naphthyl groups. Any aryl group as defined herein may be substituted with one, two or more substituents, for example F, Cl, Br, I, OH, NH₂, SH, N₃, NO₂, alkyl groups such as methyl or
30 ethyl, heteroalkyl groups such as methoxy, methylamino, dimethylamino or cyanide.

- The term heteroaryl refers to an aryl group as defined herein where one, two or more ring-carbon atoms are replaced by an oxygen, nitrogen, boron, phosphorous or sulphur atom, for example
- 5 pyridyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, tetrazolyl, pyrazinyl, pyrimidinyl and pyridazinyl groups. Any heteroaryl group as defined herein may be substituted
- 10 with one, two or more substituents, for example F, Cl, Br, I, OH, NH₂, SH, N₃, NO₂, alkyl groups such as methyl or ethyl, heteroalkyl groups such as methoxy, methylamino, dimethylamino or cyanide.
- 15 The terms arylalkyl and heteroarylalkyl refer to groups that comprise both aryl or, respectively, heteroaryl as well as alkyl and/or heteroalkyl and/or cycloalkyl groups, each of the groups as defined herein.
- 20 The terms lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkoxy alkyl and lower heteroalkyl refer to an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkoxy alkyl group and a heteroalkyl group, respectively, containing one to six carbon atoms, preferably one to four carbon
- 25 atoms.

Compounds selected from formula I of the present invention are HDM2 ligands and show binding affinities from about 1 nM to about 100 μ M to HDM2, preventing binding of p53 and other proteins,

30 inhibition of proliferation and induction of apoptosis in cell based assays.

The compounds of the present invention are useful in the treatment or control of cell proliferative disorders, in particular oncological disorders. These compounds and
5 formulations containing said compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors.

A therapeutically effective amount of a compound in accordance
10 with this invention means an amount of compound that is effective to prevent, alleviate or ameliorate symptoms of disease or prolongs the survival of the subject being treated, preferably a human. Determination of a therapeutically effective amount is within the skill in the art.

15 The therapeutically effective amount or dosage of a compound according to this invention can vary within wide limits and may be determined in a manner known in the art. Such dosage will be adjusted to the individual requirements in each particular case
20 including the specific compound being administered, the route of administration, the condition being treated, as well as the patient being treated.

Examples of pharmacologically acceptable salts of sufficiently
25 basic compounds of formula I are salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic
30 acid. Further, a sufficiently acidic compound of formula I may form alkali or earth alkaline metal salts, for example sodium,


potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris-(2-hydroxyethyl)amine, lysine or arginine salts; all of which are also further examples of salts of formula I. Compounds of formula I can be solvated, especially hydrated. The hydratization can occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of formula I. The compounds of formula I contain asymmetric C-atoms and may be present either as achiral compounds, mixtures of diastereomers, mixtures of enantiomers or as optically pure compounds.

It should be appreciated that certain compounds of formula (I) may have tautomeric forms from which only one might be specifically mentioned or depicted in the following description, different geometrical isomers (which are usually denoted as cis/trans isomers or more generally as (E) and (Z) isomers) or different optical isomers as a result of one or more chiral carbon atoms (which are usually nomenclatured under the Cahn-Ingold-Prelog or R/S system). All these tautomeric forms, geometrical or optical isomers (as well as racemates and diastereomers) and polymorphous forms are included in the invention.

Examples of different stereoisomers of the present invention are:


(3S,4S)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid

5




(3S,4R)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid

10




(3R,4R)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid



5

(3R,4S)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid




10

15


- 23 -

(3S,4S)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxy-ethyl)-amide




5

(3S,4R)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxy-ethyl)-amide




10

(3R,4R)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxy-ethyl)-amide



5

(3R,4S)-2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxy-ethyl)-amide



10

The present invention also relates to prodrugs which are composed of a compound of formula I and at least one pharmacologically acceptable protective group which will be cleaved off under physiological conditions, such as an alkoxy-, arylalkyloxy-, acyl-, acyloxymethyl group (e.g. pivaloyloxymethyl), an 2-alkyl-, 2-aryl- or 2-arylalkyl-oxy carbonyl-2-alkylidene ethyl group or an acyloxy group as defined herein, e.g. ethoxy, benzyloxy, acetyl or acetyloxy or, especially for a compound of formula I, for hydroxy group (ROH), a sulfate, a phosphate (ROPO₃ or ROCH₂OPO₃) or an ester of an amino acid. Especially preferred are prodrugs of the hydroxy group -O(X1) of a compound of formula I wherein X1 is H.

As mentioned above, therapeutically useful agents that contain compounds of formula I, their solvates, salts or formulations are also comprised in the scope of the present invention. In general, compounds of formula I will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent.

For oral administration such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups; parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension; rectal as suppositories; by inhalation or insufflation, e.g. as a powder formulation, as microcrystals or as a spray (e.g. liquid


- 26 -

aerosol); transdermal, for example via an transdermal delivery system (TDS) such as a plaster containing the active ingredient or intranasal. For the production of such tablets, pills, semisolids, coated tablets, dragees and hard, e.g. gelatine, capsules the therapeutically useful product may be mixed with pharmaceutically inert, inorganic or organic excipients as are e.g. lactose, sucrose, glucose, gelatine, malt, silica gel, starch or derivatives thereof, talc, stearinic acid or their salts, dried skim milk, and the like. For the production of soft capsules one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat, polyols. For the production of liquid solutions, emulsions or suspensions or syrups one may use as excipients e.g. water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerin, lipids, phospholipids, cyclodextrins, vegetable, petroleum, animal or synthetic oils. Especially preferred are lipids and more preferred are phospholipids (preferred of natural origin; especially preferred with a particle size between 300 to 350 nm) preferred in phosphate buffered saline (pH = 7 to 8, preferred 7.4). For suppositories one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat and polyols. For aerosol formulations one may use compressed gases suitable for this purpose, as are e.g. oxygen, nitrogen and carbon dioxide. The pharmaceutically useful agents may also contain additives for conservation, stabilization, e.g. UV stabilizers, emulsifiers, sweetener, aromatizers, salts to change the osmotic pressure, buffers, coating additives and antioxidants.

In general, in the case of oral or parenteral administration to adult humans weighing approximately 80 kg, a daily dosage of preferably from about 10 mg to about 10,000 mg, more preferably

from about 20 mg to about 1,000 mg, should be appropriate, although the upper limit may be exceeded when indicated. The daily dosage can be administered as a single dose or in separate doses, or for parenteral administration, it may be given as
 5 continuous infusion.

The compounds of the present invention can be prepared according to the following procedure:



10

An amine and an aldehyde are reacted to give an azomethine of the formula II, this azomethine is reacted with an homophthalic acid anhydride, giving compounds of formula III, which are then
 15 converted to esters, amides or left unchanged to give compounds of formula I. These compounds of formula I can be further derivatized such as making esters or salts from acids, salts from amines or cleaving protecting groups found in substituents found in R_1 to R_4 . Such methods are known for those skilled in the art
 20 (cf. e.g., J.S. Yadaf et al., Tetrahedron, 2003, 59, 1805-1809; L. Wang et al., Adv. Synth. Catal., 2005, 347, 689-694).

The present invention encompasses the following Examples.

Example 1

5

General procedure

Equimolar amounts of an aldehyde and a primary amine are added at room temperature in a solvent like dichloromethane, tetrahydrofuran, chloroform, methanol or ethanol to form the corresponding azomethine. A dehydrating agent like a mol sieve can be added to facilitate the reaction. After 1 day of reaction, equimolar amounts of a homophthalic acid anhydride derivative is added and refluxed. After 1 day of reaction the reaction mixture is cooled down. The resulting 1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid derivative is filtered off if it has precipitated out, or after removal of the solvent in vacuum, the product is re-crystallized from ethanol or purified via standard column chromatographic methods.

20 Example 2

According to the general procedure in example 1, the following compounds were prepared:

25 **2.a** 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid. Molecular Weight =426,3028, calculated from Molecular Formula =C₂₃H₁₇Cl₂NO₃. (M⁺) observed 426,5.

30 **2.b** 2,3-Bis-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid. Molecular Weight =412,2758, calculated from Molecular Formula =C₂₂H₁₅Cl₂NO₃. (M⁺) observed 412,3.

2.c 3-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid. Molecular Weight =426,3028, calculated from Molecular Formula =C23H17Cl2NO3. (M⁺) observed 426,3.

5 2.d 2-(4-Chloro-benzyl)-3-(1H-indol-3-yl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid. Molecular Weight =430,8948, calculated from Molecular Formula =C25H19ClN2O3. (M⁺) observed 431,0.

10 2.e 2-[Carboxy-(4-chloro-phenyl)-methyl]-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid. Molecular Weight =470,3128, calculated from Molecular Formula =C24H17Cl2NO5. (M⁺) observed 470,1.

15 2.f 2-(4-Chloro-benzyl)-1-oxo-3-quinolin-3-yl-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid. Molecular Weight =442,9059, calculated from Molecular Formula =C26H19ClN2O3. (M⁺) observed 443,0.

Example 3

20 General procedure:

Compounds prepared according to the general procedure in example 1 are dissolved in dimethylformamide and amine were coupled using standard peptide coupling conditions. Thus, for example the coupling agent EDCI is added to the solution of the acid in DMF,
25 reacted for 30 minutes and then the corresponding amine is added and allowed to react for 2 days at room temperature. Ethylacetate and water is then added to the reaction mixture, the organic layer is separated and washed several times with water. After removing the ethylacetate, the final product is purified either
30 by re-crystallization from ethanol or by standard column

chromatographic methods. Using this procedure, the following compounds were prepared:

5 **3.a** 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide. Molecular Weight =483.3988, calculated from Molecular Formula =C₂₆H₂₄Cl₂N₂O₃. ([M+H]⁺) observed 463.4.

10 **3.b** 2,3-Bis-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid 2-methoxyethyl-amide. Molecular Weight =469.3717, calculated from Molecular Formula =C₂₅H₂₂Cl₂N₂O₃. ([M+H]⁺) observed 469.2.

15 **3.c** 3-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide. Molecular Weight =483.3988, calculated from Molecular Formula = C₂₆H₂₄Cl₂N₂O₃. ([M+H]⁺) observed 482.1.

3.d 2-(4-Chloro-benzyl)-3-(1H-indol-3-yl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide. Molecular Weight =487.9907, calculated from Molecular Formula =C₂₈H₂₆ClN₃O₃. ([M+H]⁺) observed 488.0.

20 **3.e** 2-(4-Chloro-benzyl)-1-oxo-3-quinolin-3-yl-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide. Molecular Weight =500.0019, calculated from Molecular Formula =C₂₉H₂₆ClN₃O₃. ([M+H]⁺) observed 500.1.

25 **3.f** 2-(4-Chloro-benzyl)-3-naphthalen-2-yl-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide. Molecular Weight =499.0143, calculated from Molecular Formula =C₃₀H₂₇ClN₂O₃. ([M+H]⁺) observed 498.8.

30 **3.g** 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4-(morpholine-4-carbonyl)-3,4-dihydro-2H-isoquinolin-1-one; Molecular Weight =495,4099, calculated from Molecular Formula =C₂₇H₂₄Cl₂N₂O₃. (M⁺) observed 495,4.

- 31 -

- 3.h 4-(4-Acetyl-piperazine-1-carbonyl)-2-(4-chloro-benzyl)-3-(4-chloro-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; Molecular Weight =536,4628, calculated from Molecular Formula =C₂₉H₂₇Cl₂N₃O₃. (M⁺) observed 536,6.
- 5 3.i 4-(4-Acetyl-piperazine-1-carbonyl)-2-(4-chloro-benzyl)-3-(4-chloro-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; Molecular Weight =536,4628, calculated from Molecular Formula =C₂₉H₂₇Cl₂N₃O₃. (M⁺) observed 536,6.
- 3.j 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-hydroxy-ethyl)-amide; Molecular Weight =469,3717, calculated from Molecular Formula =C₂₅H₂₂Cl₂N₂O₃. (M⁺) observed 469,5.
- 10 3.k 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,4-dihydro-2H-isoquinolin-1-one; Molecular Weight =538,4788, calculated from Molecular Formula =C₂₉H₂₉Cl₂N₃O₃. (M⁺) observed 538,5.
- 15

Example 4

- 20 Using 4-chlorophenyl-2-amino-acetic acid methyl ester as a primary amine, (4-Chloro-phenyl)-[3-(4-chloro-phenyl)-4-(2-methoxy-ethylcarbamoyl)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid methyl ester was prepared according to the general procedure of example 1 and 3. The final acid (4-Chloro-phenyl)-
- 25 [3-(4-chloro-phenyl)-4-(2-methoxy-ethylcarbamoyl)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid was prepared by treatment with lithium hydroxide in tetrahydrofuran. Molecular Weight =527.4087, calculated from Molecular Formula =C₂₇H₂₄Cl₂N₂O₅. ([M+H]⁺) observed 526.9.

30

Example 5***In Vitro* Activity Cell-free Assay**

The ability of the compounds to bind to HDM2 and to inhibit the interaction between HDM2 and proteins that are p53-like was judged by using an ELISA (Enzyme-Linked Immuno Sorbent Assay). Test plates were prepared by coating with streptavidin followed by a PBS (phosphate-buffered saline) wash and overnight blocking with a buffer containing bovine serum albumin (BSA) in a PBS buffer. N-terminal biotinylated peptide Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu, a peptide that is homologous to the HDM2-interacting region of p53 (Blommers et al. J. Am. Chem. Soc. 1997, 119, 3425-3426) is added to each well in blocking buffer and washed after incubation. Test compounds were incubated with a mix of the HDM2 protein and an anti-HDM2 antibody (SMP-14, Santa Cruz Biotech) in a separate plate. After incubation, the content of the plate is transferred and incubated in the test plate. The secondary anti-mouse IgG antibody (peroxydase linked anti-mouse IgG, Roche Molecular Biochemicals) is added to the test plate preceded and followed by a wash with 0.05% Tween 20 in PBS. Finally, peroxydase substrate (MTB Microwell Peroxydase Substrate System, Kirkegaard & Perry Labs) is added to each well and the absorption was read at 450 nm. The inhibitory activity of the test compounds was measured as a percentage of the bound HDM2 in treated vs. untreated wells and IC50 was calculated.

Example 6***In Vitro* Activity Cell-free Assay**


The ELISA plates (MaxiSorp-Nunc) were coated with GST-HDM2 protein or GST protein diluted in PBS as a control. After washing

- 33 -

with a solution containing PBS, the plates were incubated with blocking solution containing BSA/mL and washed. A solution of the compounds to be tested on p53 protein was incubated. After an additional washing, the plates were incubated with the monoclonal antibody Pab42123 (Oncogene Science) in a blocking solution. The plates were washed and incubated with a goat antimouse IgG antibody coupled to alkaline phosphatase (Promega) diluted in blocking solution. The excess of antibody was removed with washing solution, and the coupled antibody was detected with a solution of p-nitrophenyl phosphate salt. The absorbance was measured at 405 nm.

Claims

1. A compound of formula I and pharmaceutically acceptable salts and esters thereof,



formula I

wherein R1 is selected from substituted or unsubstituted morpholinyl, substituted or unsubstituted pyrrolidinyl and substituted or unsubstituted piperazinyl, -O(X1) or -NX1(X2), with X1 and X2 independently selected from H, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl,

wherein R2 and R3 are independently selected from aryl, heteroaryl, arylalkyl or heteroarylalkyl,

wherein R4 is selected from -H, -F, -Cl, -Br, -I, -NO2, hydroxy, lower alkyl, lower alkenyl or lower alkynyl, lower alkoxy, such as -OCH3, -CH2OCH3 and -CH2OCH2CH3, -NY1(Y2), with Y1 and Y2 independently selected from H, lower alkyl, lower alkoxy alkyl, hetero alkyl, aryl or heteroaryl.

2. A compound according to claim 1, wherein R2 and R3 are each independently selected from aryl, heteroaryl, 1H-indol-3-yl, naphthal-2-yl, quinolin-3-yl, phenyl, substituted phenyl, 3- or 4-fluorophenyl, 3- or 4-

- 35 -

chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl, benzyl, substituted benzyl, 3- or 4-fluorobenzyl, 3- or 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl.

- 5 3. A compound according to claim 1, wherein R2 is selected from phenyl, substituted phenyl, 1H-indol-3-yl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorophenyl, 3- or 4-chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl and R3 is selected from benzyl, substituted benzyl, 1H-indol-10 3-methyl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorobenzyl, 3- or 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl.
- 15 4. A compound according to claim 1, wherein R2 is selected from benzyl, substituted benzyl, 1H-indol-3-methyl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorobenzyl, 3- or 4-chlorobenzyl, 3- or 4-bromobenzyl, 3- or 4-iodobenzyl and R3 is selected from phenyl, substituted phenyl, 1H-20 indol-3-yl, naphthal-2-yl, quinolin-3-yl, 3- or 4-fluorophenyl, 3- or 4-chlorophenyl, 3- or 4-bromophenyl, 3- or 4-iodophenyl.
- 25 5. A compound according to any one of claims 1 to 4, wherein R1 is selected from dimethylaminyl, diethylaminyl, morpholinyl, piperazinyl, N-methyl-piperazinyl, N-acetyl-30 piperazinyl, N-2-hydroxyethyl-piperazinyl, 2-oxo-N-alkyl-piperazinyl, 2-oxo-N-heteroalkyl-piperazinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl or 2-carboxy-pyrrolidinyl.

6. A compound according to any one of claims 1 to 4, wherein R1 is selected from -OX1 or -NH(X2), wherein X1 is selected from -H or lower alkyl, and X2 is selected from H, -CH₂CH₂OH, -CH₂CH₂OCH₃, lower alkyl, lower heteroalkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl.

7. A compound according to claim 1, selected from the group of: 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2,3-Bis-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 3-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2-(4-Chloro-benzyl)-3-(1H-indol-3-yl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; (4-Chloro-phenyl)-[3-(4-chloro-phenyl)-4-(2-methoxyethylcarbamoyl)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid; 2-(4-Chloro-benzyl)-1-oxo-3-quinolin-3-yl-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2-(4-Chloro-benzyl)-3-naphthalen-2-yl-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-methoxyethyl)-amide; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2,3-Bis-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 3-(4-Chloro-benzyl)-2-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-(1H-indol-3-yl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-[Carboxy-(4-chloro-phenyl)-methyl]-3-

(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-1-oxo-3-quinolin-3-yl-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4-(morpholine-4-carbonyl)-3,4-dihydro-2H-isoquinolin-1-one; 4-(4-Acetyl-piperazine-1-carbonyl)-2-(4-chloro-benzyl)-3-(4-chloro-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; 4-(4-Acetyl-piperazine-1-carbonyl)-2-(4-chloro-benzyl)-3-(4-chloro-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-1-oxo-1,2,3,4-tetrahydro-isoquinoline-4-carboxylic acid (2-hydroxy-ethyl)-amide; 2-(4-Chloro-benzyl)-3-(4-chloro-phenyl)-4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,4-dihydro-2H-isoquinolin-1-one.

8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable ester, prodrug, hydrate, solvate or salt thereof, optionally in combination with a pharmaceutically acceptable carrier.

9. A pharmaceutical composition according to claim 8 comprising one or more other anti-tumor agents.

10. A pharmaceutical composition according to claim 9, wherein the anti-tumor agent is selected from 16-Aza-epothilone B, Aldesleukin, Amifostine, Aranose, Bevacizumab, Bleocin, Bleomycin, BMS-184476, Bortezomib, Calcitriol, Carmustine, Canertinib, Canfosfamide, Capecitabine, Carboplatin, Carmustine, Cefixime, Ceftriaxone, Celecoxib, Celmoleukin, Cetuximab,

- 38 -

Ciclosporin, Cisplatin, Clodronate, Cyclophosphamide,
Cytarabine, Deoxorubicin, Desoxyepothilone B,,
Diethylstilbestrol, Diflomotecan, Docetaxel, Doxorubicin,
Edatrexate, Efaproxiral, EKB-569, Epirubicin,
5 Epratuzumab, Erlotinib, Etoposide, Exatecan, Fludarabine,
Fluorouracil, Folinic acid, Galarubicin, Gefinitib,
Gemcitabine, Gemtuzumab, Gimatecan, Glufosfamide,
Granisetron, Homoharringtonine, Hyaluronic acid,
Ibandronate, Ibritumomab, Ifosfamide, Imatinib,
10 Interferon alfa, Interferon alfa-2a, Interferon alfa-2b,
Irinotecan, Isoflavone, Isotretinoin, Ixabepilone,
Ketoconazole, Lapatinib, Leflunomide, Lenograstim,
Leucovorin, Lexidronam, Linezolid, Lometrexol,
Lurtotecan, MEN-10755, Methotrexate, Mitomycin,
15 Neridronate, Nimesulide, Nitroglycerin, O6-Benzylguanine,
Omeprazole, Ortataxel, Oxaliplatin, Paclitaxel,
Patupilone, Pegfilgrastim, PEG-filgrastim, Pelitinib,
Pemetrexed, Pentostatin, Perifosine, Plevitrexed,
Polyprenoic acid, Quinupristin, Raloxifene, Raltitrexed,
20 Ramosetron, Retinoic acid, Risedroante, Rituximab,
Rofecoxib, Rubitecan, S-9788, Sabarubicin, Sargramostim,
Satraplatin, SN-38, Sorafenib, Suberanilohydroxamic acid,
Tamoxifen, Taxotere, Tazarotene, Tegafur, Temozolamide,
Tesmiflifen, Tetrodotoxin, Thalidomide, Tipifarnib,
25 Topotecan, Trabectedin, Trastuzumab, Traszutumab,
Tretinoin, Vatalanib, Vincristine, Vinorelbine,
Vinscristine, ZD-6474, Zoledronate or Zosuquidar.

11. A pharmaceutical composition according to any one of
30 claims 8 to 10 comprising one or more antitviral agents.

- 39 -

12. A pharmaceutical composition according to claim 11,
wherein the antiviral agent is selected from 3TC,
Abacavir, Adefovir dipivoxil, Acyclovir, Amprenavir,
Amantadine, Amoxovir, AZT, Clevudine, Delavirdine, d4T,
5 Emtricitabine, Entecavir, Famciclovir, Ganciclovir,
Indinavir, Lamivudine, Nelfinavir, Nevirapine,
Oseltamavir, Rimantadine, Ritonavir, Saquinavir, Septrin,
Telbivudine, Tenofovir, Valacyclovir, Valtorcitabine,
Valopicitabine or Zanamivir.

10 13. Use of a compound or a pharmaceutical composition
according to any one of claims 1 to 12 for the
preparation of a medicament for the treatment of cancer.

15

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/002471

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D217/24 A61K31/435 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12, 5 December 2003 (2003-12-05) & JP 2003 313168 A (KIRIN BREWERY CO LTD), 6 November 2003 (2003-11-06) cf. esp. cpd. 97 abstract	1-13
A	US 2004/220179 A1 (LU TIANBAO ET AL) 4 November 2004 (2004-11-04) the whole document	1-13
A	WO 03/095625 A (3-DIMENSIONAL PHARMACEUTICALS, INC; KOBLISH, HOLLY, K; MANTHEY, CARL,) 20 November 2003 (2003-11-20) cited in the application the whole document	1-13

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

17 July 2006

Date of mailing of the international search report

25/07/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fritz, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/002471

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 2003313168	A	06-11-2003	NONE	
US 2004220179	A1	04-11-2004	NONE	
WO 03095625	A	20-11-2003	AU 2003235504 A1	11-11-2003